Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC
Zongertinib is now approved by the FDA for patients with nonsquamous NSCLC with HER2 TKD activating mutations.
Previous Post
Left Bundle Branch Block May Be Key Indicator of Progressive Heart Failure
Next Post
Availity, Onyx Launch Turnkey Solution to Meet Prior Authorization, Interoperability Rule
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago